Division of Boston Scientific Corp.
Latest From Symetis SA
French VC firm Truffle Capital has raised €250 million ($278m) for its new BioMedTech fund. The capital will be used to create 12 new medtech companies.
While other venture capitalists are curbing their efforts in medtech, Wellington Partners intends to maintain its support for the sector earmarking about half of its new €210m WPLS-V fund for European medtech opportunities.
With its WPLS-IV fund now fully committed, Wellington Partners has returned to the market and raised €210m in its WPLS-V fund which will focus on European biotech and medtech opportunities.
Boston Scientific has inked a deal of up to $270m for embolic protection system developer Claret Medical, marking its second acquisition in the space of two weeks.
- Implantable Devices
Surgical Equipment & Devices
- Minimally or Less Invasive
- Therapeutic Areas
- Western Europe
- Parent & Subsidiaries
- Boston Scientific Corp.
- Senior Management
Jacques R Essinger, PhD, CEO
Khaled Bahi, CFO
Stéphane Delaloye, PhD, VP, R&D
Francis Jannot, VP, Sales & Mktg.
- Contact Info
Phone: (41) 21650 0160
chemin de la venoge 11
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.